Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dyadic InternationalDYAI +3.89%38 Cash-to-Debt is 0.62 as of Jun. 2026, which is 100% below its 10-year median of 10,000.00. GuruFocus rates DYAI with a GF Score™ of 38/100 and a GF Value™ of $0.57 (Fairly Valued). The stock has 7 warning signs investors should review. Among 1,398 Biotechnology companies, Dyadic International ranks worse than 82.83% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Dyadic International's cash to debt ratio for the quarter that ended in Jun. 2026 was 0.62.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Dyadic Internationalcouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Dyadic International's Cash-to-Debt or its related term are showing as below:
DYAI'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.62 Med: No Debt Max: No Debt
Current: 0.62
During the past 13 years, Dyadic International's highest Cash to Debt Ratio was No Debt. The lowest was 0.62. And the median was No Debt.
DYAI's Cash-to-Debt is ranked worse than 82.83% of 1398
companies
in the Biotechnology industry
Industry Median: 6.575
vs DYAI: 0.62
Dyadic International (NAS:DYAI) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Dyadic International Cash-to-Debt Related Terms
Dyadic International Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Dyadic International's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Dyadic International's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dyadic International Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Dyadic International's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Dyadic International's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dyadic International (DYAI) has a Cash-to-Debt of 0.62 as of Jun. 2026. This is 100% below median its historical median of 10,000.00. Over the past decade, Dyadic International's Cash-to-Debt has ranged from 0.62 to 10,000.00. According to the industry distribution chart, Dyadic International ranks #1158 out of 1398 companies in the Biotechnology industry, placing it in the top 82.8%.
Is Dyadic International's Cash-to-Debt too high?
Dyadic International's current Cash-to-Debt of 0.62 is 100% below median its 10-year median of 10,000.00. Over the past 10 years, this metric has ranged from a low of 0.62 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 6.58. Dyadic International's value of 0.62 is 90.6% below this industry median. Based on the distribution chart, Dyadic International ranks #1158 out of 1398 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Dyadic International has a GF Score™ of 38/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Dyadic International's Cash-to-Debt compare to PVCT and TVRD?
According to the Biotechnology industry distribution chart, Dyadic International ranks #1158 out of 1398 companies for Cash-to-Debt. This places Dyadic International in the lower half of its industry. The industry median Cash-to-Debt is 6.58. Dyadic International's value of 0.62 is 90.6% below this benchmark. Historically, Dyadic International's own Cash-to-Debt has ranged from 0.62 to 10,000.00 over the past decade. While the company's 10-year median is 10,000.00 vs. the industry median of 6.58, Dyadic International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.58, based on 1,398 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dyadic International's current Cash-to-Debt of 0.62 is 90.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dyadic International's current Cash-to-Debt is 0.62, which is 100% below median its own 10-year median of 10,000.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dyadic International stock overvalued right now?
Based on GuruFocus' analysis, Dyadic International (DYAI) is currently considered Fairly Valued. The stock's GF Value™ is $0.57, compared to a current price of $0.53 — trading 7.8% below its estimated fair value. The current Cash-to-Debt is 0.62, which is 100% below median its 10-year median of 10,000.00 and 90.6% below the Biotechnology industry median of 6.58. Dyadic International's overall GF Score™ is 38/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Dyadic International (DYAI), the current Cash-to-Debt is 0.62 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dyadic International (DYAI) Overvalued in 2026?
Based on GuruFocus' analysis, Dyadic International stock appears to be undervalued.
The current stock price of $0.53 is trading 7.8% below its estimated GF Value™ of $0.57.
GuruFocus considers Dyadic International to be Fairly Valued.
Key valuation signals for DYAI:
Cash-to-Debt: 0.62 (100% below median its 10-year median of 10,000.00)
GF Value™: $0.57 vs. price of $0.53 (7.8% below fair value)
Industry Position: 90.6% below the Biotechnology median (#1158 of 1398)
No single metric tells the full story. See the DYAI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
38GF Score
Get the complete analysis for DYAI
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DYAI has been successfully added to your 
